Clinical Trial - NCT02977780

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Recruiting

Sponsor: Dana-Farber Cancer Institute

Collaborators: Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure

Information provided by (Responsible party): Principal Investigator Dana-Farber Cancer Institute Brian Alexander, MD Director, CNS Radiation Oncology

ClinicalTrials.gov Identifier: NCT02977780

Protocol Info

Short Description: Individualized Screening + Therapy in Glioblastoma
Long Description: Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)
MGH Status: Open
Sponsor: DF/HCC
Disease Program: Brain/CNS

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : - Abemaciclib - Temozolomide (temodar) - Neratinib - CC115
Condition Title Intervention Phase
Glioblastoma Temozolomide Neratinib CC-115 Abemaciclib Phase 2
Study Type Interventional
Official Title INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Primary Outcome Measures

Overall Survival in Experimental Arms Compared with Standard Therapy [Time Frame: 2 years] [Designated as safety issue: ]


Secondary Outcome Measures

Incidence of Treatment-Emergent Adverse Events [Time Frame: 2 years] [Designated as safety issue: ]

Progression Free Survival Among Experimental Arms And Biomarker Groups [Time Frame: 2 years] [Designated as safety issue: ]

Overall Survival Among Experimental Arms And Biomarker Groups [Time Frame: 2 years] [Designated as safety issue: ]

Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents [Time Frame: 2 years] [Designated as safety issue: ]

Estimated Enrollment: 280
Study Start Date: February 2017
Estimated Study Completion Date: May 2021
Estimated Primary Completion Date: May 2019
Arms Assigned Interventions

Active Comparator:Temozolomide

Daily Radiation for a maximum of 49 days. Temozolomide will be administered orally on a daily dosing schedule Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)
Drug:Temozolomide
Temzolomide capsules

Experimental:Abemaciclib with Temozolomide

Daily Radiation for a maximum of 49 days. Temozolomide will be administered orally on a daily dosing schedule during radiation Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy Abemaciclib will be taken post radiation at a twice daily oral pre-determined dose
Drug:Abemaciclib
Abemaciclib capsules

Experimental:CC-115

Twice daily oral dosing of CC-115 Daily Radiation for a maximum of 49 days CC115 will also be taken twice daily post radiation
Drug:CC-115
CC-115 capsule

Experimental:Neratinib with Temozolomide

Daily Radiation for a maximum of 49 days. Temozolomide will be administered orally on a daily dosing schedule Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy Neratinib will be taken post radiation at a daily oral pre-determine dose
Drug:Neratinib
Neratinib tablets

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

  • Participants must have histologically confirmed intracranial glioblastoma or gliosarcoma following maximum surgical resection. Tumors primarily localized in the infratentorial compartment will be excluded.
  • Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy.
  • Age ≥ 18 years.
  • Karnofsky performance status ≥60
  • Participants must have normal organ and marrow function as defined below:
  • Leukocytes ≥3,000/mL
  • Absolute neutrophil count ≥1,500/mL
  • Platelets ≥100,000/mL
  • Hemoglobin ≥ 9g/dl
  • Total bilirubin within normal institutional limits (except for participant's with Gilbert's disease)
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
  • Creatinine ≤ institutional upper limit of normal OR
  • Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  • Potassium within normal institutional range, or correctable with supplements
  • Serum amylase ≤ 1.5 x institutional upper limit of normal
  • Serum lipase ≤ 1.5 x institutional upper limit of normal
  • INR < 2.0
  • PTT ≤ institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin
  • Must be able to swallow pills.
  • Participants must plan to begin radiation therapy 14-42 days after surgical resection.
  • Immunohistochemically negative for IDH1 R132H mutation.
  • Evidence that the tumor MGMT promoter is unmethylated by standard of care assays.
  • Genotyping data available or in process (data must be available at time of initial registration if randomization probabilities differ across biomarker subgroups as determined by the DFCI Coordinating Center) to assign biomarker subgroups through whole exome sequencing, whole genome copy number analysis, or a combination as described in Section 9.1.
  • MRI with gadolinium should be obtained within 21 days prior to beginning treatment. Patients without measurable disease are eligible. Participants must be able to undergo MRIs (CTs are not allowed for response assessment on study).
  • The effects of the experimental agents used in this study on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (women who are not free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation unless otherwise specified in sub-study that the participant is randomized to. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • For women of child bearing potential (women who are not free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) a negative serum pregnancy test must be documented prior to initial registration.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants will not be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis revealed glioblastoma.
  • Planned major surgery.
  • Participants who are receiving any other investigational agents.
  • Participants who have had any prior cranial radiotherapy.
  • Planned use of Optune™.
  • History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, and/or (b) malignancy was cervical cancer in situ, superficial bladder cancer or basal cell or squamous cell carcinoma of the skin, and malignancy has been treated. Patients who meet the above listed criteria and are only on preventative treatment will be deemed eligible.
  • History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
  • Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
  • Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia.
  • Known history of congenital QT prolongation or Torsade de pointes (TdP).
  • Complete left bundle branch or bifascicular block.
  • -QTc interval > 450 ms for men or > 470 ms for women.
  • Persistent or history of clinically meaningful ventricular arrhythmias or atrial fibrillation.
  • Unstable pectoris or myocardial infarction ≤ 3 months prior to starting study treatment.
  • Uncontrolled hypertension (blood pressure ≥ 160/95 mmHg).
  • Other clinically significant heart disease such as congestive heart failure requiring treatment.
  • Uncontrolled diabetes mellitus, or subjects with either of the following:
  • Fasting blood glucose (FBG defined as fasting for at least 8 hours) ≥ 200 mg/dL (7.0 mmol/L), or
  • HbA1c ≥ 8%
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, chronic liver disease (e.g., cirrhosis, hepatitis), chronic renal disease, pancreatitis, chronic pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements. Subjects must be free of any clinically relevant disease (other than glioma) that would, in the treating investigator's opinion, interfere with the conduct of the study or study evaluations.
  • Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNS [qualitative] is detected).
  • Known acute or chronic pancreatitis.
  • Participants with active diarrhea ≥ CTCAE grade 2 despite medical management.
  • Active infection requiring antibiotics.
  • Pregnant or breastfeeding.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive small bowel resection). Participants with unresolved diarrhea ≥ CTCAE grade 2 will be excluded as previously indicated.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study.
  • Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least 7 days prior to planned start of study treatment. A list of EIAED and other inducers of CYP3A4 is provided. Among non-EIAED, caution is recommended with use of valproic acid due to potential for drug interaction.
  • Participants taking a drug known to be strong inhibitors or inducers of isoenzyme CYP3A. Participant must be off CYP3A inhibitors and inducers for at least 7 days prior to planned start of study treatment. NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to planned start of study treatment and during the entire study treatment period due to potential CYP3A4 interaction.
  • Current use of herbal preparations/medications, including but not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng. Participants should stop using these herbal medications 7 days prior to planned start of study treatment.
  • Current use of warfarin sodium or any other coumadin-derivative anticoagulant. Participant must be off Coumadin-derivative anticoagulants for at least 7 days prior to planned start of study treatment. Low molecular weight heparin and factor Xa inhibitors are allowed.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02977780

Locations

  • United States, Alabama
    • University of Alabama at Birmingham Birmingham, Alabama, United States, 35294
  • United States, Massachusetts
    • Massachusetts General Hospital Boston, Massachusetts, United States, 02114
    • Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115
  • United States, Minnesota
    • Mayo Clinic Rochester, Minnesota, United States, 55905
  • United States, New York
    • Columbia University Medical Center New York, New York, United States, 10032
  • United States, Ohio
    • Cleveland Clinic Cleveland, Ohio, United States, 44195
  • United States, Pennsylvania
    • University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232
  • United States, Texas
    • UT MD Anderson Cancer Center Houston, Texas, United States, 77030
  • United States, Utah
    • Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112
  • United States, Virginia
    • University of Virginia Health System Charlottesville, Virginia, United States, 22908

Sponsors and Collaborators

Dana-Farber Cancer Institute

Eli Lilly and Company

Celgene

Puma Biotechnology, Inc.

Accelerate Brain Cancer Cure

More Information

No publications provided

Responsible Party: Principal Investigator Dana-Farber Cancer Institute Brian Alexander, MD Director, CNS Radiation Oncology
ClinicalTrials.gov Identifier: NCT02977780
Other Study ID Numbers:
Study First Received:
Last Updated:
Health Authority:

Keywords provided by Dana-Farber Cancer Institute:

Glioblastoma

Additional relevant MeSH terms:

Glioblastoma

Temozolomide

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on August 15, 2019